Auranofin prevents liver fibrosis by system Xc-mediated inhibition of NLRP3 inflammasome

Previous studies showed that the anti-rheumatic agent auranofin inhibits the NLRP3 inflammasome; thus, this study evaluate the anti-fibrotic effect of auranofin in vivo and explored the underlying molecular mechanism. The antifibrotic effect of auranofin is assessed in thioacetamide- and carbon tetrachloride-induced liver fibrosis models. In this study, we use RNA-sequencing in hepatic stellate cell (HSC), and bone marrow-derived macrophage (BMDM) to examine the underlying mechanism of auranofin. Overall design: Examination of difference between Auranofin-treated group and un-treated group in activated hepatic stellate cell and bone marrow derived macrophage.